MedPath

Magseed Magnetic Marker Localization

Not Applicable
Completed
Conditions
Disorders of Breast
Breast Lesions
Interventions
Device: Magseed and Sentimag
Registration Number
NCT03020888
Lead Sponsor
Endomagnetics Inc
Brief Summary

The purpose of this post-marketing study is to provide prospective evidence that the Magseed and Sentimag® is effective for lesion localization in patients undergoing surgical excision of a breast lesion and to summarize measures of product safety and performance.

Detailed Description

This is a post-market, prospective, open label, single arm study of Magseed and Sentimag in patients undergoing surgical excision of a breast lesion.

Subjects will have the Magseed marker deployed under imaging guidance up to thirty days prior to surgery.

The Magseed marker will be localized using the Sentimag system during surgery and removed with the lesion.

After the lumpectomy procedure, subjects will be evaluated for safety and patient reported outcomes.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
120
Inclusion Criteria
  • Subjects with a breast lesion requiring image-guided localization prior to excision.
  • Subjects aged 18 years or more at the time of consent.
Exclusion Criteria
  • The subject is pregnant or lactating.
  • Subject has pacemaker or other implantable device in the chest wall.
  • Subject has current active infection at the implantation site in the breast (per investigatordiscretion)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Magseed and SentimagMagseed and SentimagMagseed marker deployed to mark a breast lesion under imaging guidance up to 30 days prior to surgery. Marker located during surgery using the Sentimag system, and removed with the lesion.
Primary Outcome Measures
NameTimeMethod
Percent of Participants With Retrieval of Index Lesion and MagseedTime of surgery on average 16 minutes

Percent retrieval rate of the index lesion and Magseed in the initial excised specimen. This is defined as the number of subjects in whom the index lesion and Magseed are retrieved in the initial excised specimen divided by the total number of subjects undergoing surgery.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants With Re-excisionDuring surgery on average 16 minutes

Overall re-excision rate and re-excision rate necessary to remove the Magseed or targeted lesion

Number of Device Related Adverse Events8 weeks

Rates of device-related adverse events and device-related serious adverse events

Surgical Localization - Duration of LocalizationAt time of surgery on average 16 minutes

Duration of the lumpectomy procedure, time taken to remove the lesion

Percent of Participants With Radiological Ease of Placement Rated as Very Easy, or Fairly EasyAt the time of marker deployment on average 8.39 minutes

Radiologist were asked to rate ease of marker placement graded from Very easy, Fairly Easy \& Difficult after each marker placement.

Percentage of Markers With Radiological Placement Accuracy Measured as <5mm to LesionAt time of marker deployment on average 8.39 minutes

Success rate of Magseed placement relative to the lesion (placement accuracy) measured as \<5mm to lesion; 5-10mm to lesion; \>10 mm to the target

Percent of Participants With Surgical Ease of Localization - Rated Fairly or Very EasyAt time of surgery on average 16 minutes

Surgeon rated ease of localization during surgery assessed for each procedure as either very easy, fairly easy, fairly difficult, difficult, unable to localise

Percentage of Participants With Marker Retrieval Rated as Fairly or Very EasyOn the day of surgery

Pathologist rated ease of marker identification and retrieval as: 1) Unable to retrieve 2) Difficult 3) Fairly difficult 4)fairly easy 5) very easy

Trial Locations

Locations (1)

University of Texas MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath